21 CFR § 660.28 - Labeling.
(a) In addition to the applicable labeling requirements of §§ 610.62 through 610.65 and § 809.10 of this chapter, and in lieu of the requirements in §§ 610.60 and 610.61 of this chapter, the following requirements shall be met:
(1) Final container label—(i) Color coding. The final container label of all Blood Grouping Reagents shall be completely white, except that all or a portion of the final container label of the following Blood Grouping Reagents may be color coded with the specified color which shall be a visual match to a specific color sample designated by the Director, Center for Biologics Evaluation and Research. Printing on all final container labels shall be in solid black. A logo or company name may be placed on the final container label; however, the logo or company name shall be located along the bottom or end of the label, outside the main panel.
| Blood grouping reagent | Color of
label paper |
|---|---|
| Anti-A | Blue. |
| Anti-B | Yellow. |
| Slide and rapid tube test blood grouping reagents only: | |
| Anti-C | Pink. |
| Anti-D | Gray. |
| Anti-E | Brown. |
| Anti-CDE | Orange. |
| Anti-c
|
Lavender. |
| Anti-e | Green. |
(ii) Required information. The proper name “Blood Grouping Reagent” need not appear on the final container label provided the final container is distributed in a package and the package label bears the proper name. The final container label shall bear the following information:
(A) Name of the antibody or antibodies present as set forth in paragraph (a)(4) of this section.
(B) Name, address (including ZIP code), and license number of the manufacturer.
(C) Lot number, including sublot designations.
(D) Expiration date.
(E) Source of product if other than human plasma or serum.
(F) Test method(s) recommended.
(G) Recommended storage temperature in degrees Celsius.
(H) Volume of product if a liquid, or equivalent volume for a dried product if it is to be reconstituted.
(I) If a dried product, to remind users to record the reconstitution date on the label, the statement “RECONSTITUTION DATE ___. EXPIRES 1 YEAR AFTER RECONSTITUTION DATE.”
(iii) Lettering size. The type size for the specificity of the antibody designation on the labels of a final container with a capacity of less than 5 milliliters shall be not less than 12 point. The type size for the specificity of the antibody designations on the label of a container with a capacity of 5 milliliters or more shall be not less than 18 point.
(iv) Visual inspection. When the label has been affixed to the final container, a sufficient area of the container shall remain uncovered for its full length or no less than 5 millimeters of the lower circumference to permit inspection of the contents. The label on a final product container for antibodies Anti-c, Anti-k, or Anti-s shall display a bar immediately over the specificity letter used in the name, i.e., Anti-c
, Anti-k , or Anti-s .(2) Package label. The following information shall appear either on the package label or on the final container label if it is visible within the package.
(i) Proper name of the product.
(ii) Name of the antibody or antibodies present as set forth in paragraph (a)(4) of this section.
(iii) Name, address (including ZIP Code), and license number of the manufacturer.
(iv) Lot number, including sublot designations.
(v) Expiration date.
(vi) Preservative used and its concentration.
(vii) Number of containers, if more than one.
(viii) Volume or equivalent volume for dried products when reconstituted, and precautions for adequate mixing when reconstituting.
(ix) Recommended storage temperature in degrees Celsius.
(x) Source of the product if other than human serum or plasma.
(xi) Reference to enclosed package insert.
(xii) If a dried product, a statement indicating the period within which the product may be used after reconstitution.
(xiii) The statement: “FOR IN VITRO DIAGNOSTIC USE.”
(xiv) The statement: “MEETS FDA POTENCY REQUIREMENTS.”
(xv) If human blood was used in manufacturing the product, the statement: “CAUTION: ALL BLOOD PRODUCTS SHOULD BE TREATED AS POTENTIALLY INFECTIOUS. SOURCE MATERIAL FROM WHICH THIS PRODUCT WAS DERIVED WAS FOUND NEGATIVE WHEN TESTED IN ACCORDANCE WITH CURRENT FDA REQUIRED TESTS. NO KNOWN TEST METHODS CAN OFFER ASSURANCE THAT PRODUCTS DERIVED FROM HUMAN BLOOD WILL NOT TRANSMIT INFECTIOUS AGENTS.”
(xvi) A statement of an observable indication of an alteration of the product, e.g., turbidity, color change, precipitate, that may indicate possible deterioration of the product.
(3) Package insert. Each final container of Blood Grouping Reagent shall be accompanied by a package insert meeting the requirements of § 809.10. If two or more final containers requiring identical package inserts are placed in a single package, only one package insert per package is required.
(4) Names of antibodies.
Blood Group Designation for Container Label
| Anti-A | Anti-Jk b |
|---|---|
| Anti-A1 | Anti-Js a |
| Anti-A, B | Anti-Js b |
| Anti-A and B | Anti-K |
| Anti-B | Anti-k
|
| Anti-C | Anti-Kp a |
| Anti-C w | Anti-Kp b |
| Anti- c
|
Anti-Le a |
| Anti-CD | Anti-Le b |
| Anti-CDE | Anti-Lu a |
| Anti-Co b | Anti-Lu b |
| Anti-D | Anti-M |
| Anti-DE | Anti-M g |
| Anti-Di a | Anti-N |
| Anti-E | Anti-P1 |
| Anti-e | Anti-S |
| Anti-Fy a | Anti-s
|
| Anti-Fy b | Anti-U |
| Anti-I | Anti-Wr a |
| Anti-Jk a | Anti-Xg a |
(b) The applicant may provide the labeling information referenced in paragraph (a) of this section in the form of:
(1) A symbol accompanied by explanatory text adjacent to the symbol;
(2) A symbol not accompanied by adjacent explanatory text that:
(i) Is contained in a standard that FDA recognizes under its authority in section 514(c) of the Federal Food, Drug, and Cosmetic Act;
(ii) Is used according to the specifications for use of the symbol set forth in FDA's section 514(c) recognition; and
(iii) Is explained in a paper or electronic symbols glossary that is included in the labeling for the device and the labeling on or within the package containing the device bears a prominent and conspicuous statement identifying the location of the symbols glossary that is written in English or, in the case of articles distributed solely in Puerto Rico or in a Territory where the predominant language is one other than English, the predominant language may be used; or
(3) A symbol not accompanied by adjacent explanatory text that:
(i) Is established in a standard developed by a standards development organization (SDO);
(ii) Is not contained in a standard that is recognized by FDA under its authority in section 514(c) of the Federal Food, Drug, and Cosmetic Act or is contained in a standard that is recognized by FDA but is not used according to the specifications for use of the symbol set forth in FDA's section 514(c) recognition;
(iii) Is determined by the manufacturer to be likely to be read and understood by the ordinary individual under customary conditions of purchase and use in compliance with section 502(c) of the Federal Food, Drug, and Cosmetic Act;
(iv) Is used according to the specifications for use of the symbol set forth in the SDO-developed standard; and
(v) Is explained in a paper or electronic symbols glossary that is included in the labeling for the device and the labeling on or within the package containing the device bears a prominent and conspicuous statement identifying the location of the symbols glossary that is written in English or, in the case of articles distributed solely in Puerto Rico or in a Territory where the predominant language is one other than English, the predominant language may be used.
(c) The use of symbols in device labeling to provide the labeling information referenced in paragraph (a) of this section which do not meet the requirements in paragraph (b) of this section renders a device misbranded under section 502(c) of the Federal Food, Drug, and Cosmetic Act.
(d) For purposes of paragraph (b) of this section:
(1) An SDO is an organization that is nationally or internationally recognized and that follows a process for standard development that is transparent, (i.e., open to public scrutiny), where the participation is balanced, where an appeals process is included, where the standard is not in conflict with any statute, regulation, or policy under which FDA operates, and where the standard is national or international in scope.
(2) The term “symbols glossary” means a compiled listing of:
(i) Each SDO-established symbol used in the labeling for the device;
(ii) The title and designation number of the SDO-developed standard containing the symbol;
(iii) The title of the symbol and its reference number, if any, in the standard; and
(iv) The meaning or explanatory text for the symbol as provided in the FDA recognition or, if FDA has not recognized the standard or portion of the standard in which the symbol is located or the symbol is not used according to the specifications for use of the symbol set forth in FDA's section 514(c) recognition, the explanatory text as provided in the standard.